Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201407160 Principal Investigator: Carson, Kenneth
Title: A multicenter phase I dose-finding and preliminary efficacy study of the histone deacetylase inhibitor romidepsin (Istodax) in combination with gemcitabine (Gemzar), oxaliplatin (Eloxatin), and dexamethasone for the treatment of adults with relapsed/refractory aggressive lymphomas
Description: The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD. GemOxD is a routine treatment for your type of lymphoma, and involves the administration of three drugs: gemcitabine, oxaliplatin, and dexamethasone...MORE
___________________________________________________________________________________________________
 Number: 201404056 Principal Investigator: Bartlett, Nancy
Title: A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Description: The purpose of this research study is to find the maximum tolerated dose of two drugs being given in combination for the treatment of your disease: brentuximab vedotin and lenalidomide. We also want to look at the side effects of giving these drugs together, as well as how your disease responds to t...MORE
___________________________________________________________________________________________________
 Number: 201101864 Principal Investigator: Stockerl-Goldstein, Keith
Title: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Description: You may be invited to participate in a research study to treat non-Hodgkin’s lymphoma. The treatment plan consists of an autologous hematopoietic (blood) cell transplant followed by a non-myeloablative allogeneic transplantation (transplant from another individual). An autologous transplant is don...MORE
___________________________________________________________________________________________________
 Number: CTSU S1001 Principal Investigator: Bartlett, Nancy
Title: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) (S1001)
Description: This study uses a radiologic test called a PET/CT scan to determine treatment after initial doses of a standard FDA approved chemotherapy regimen called "R-CHOP". The purpose of the study is to give more intensive treatment to patients whose PET/CT scan shows that they are at a greater chance of sti...MORE
___________________________________________________________________________________________________
 Number: CTSU 9177 Principal Investigator: Bartlett, Nancy
Title: Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma (9177)
Description: The purpose of this research study is to compare the good and/or bad effects of an investigational approach to treating certain types of lymphoma....MORE
___________________________________________________________________________________________________
 Number: CTEP 9534 Principal Investigator: Bartlett, Nancy
Title: A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients with Previously Treated Mantle Cell Lymphoma (9534)
Description: The purpose of this study is to test the safety of the combination of ibrutinib plus palbociclib at different doses in patients with mantle cell lymphoma to find out what effects, if any, they have on patients and to determine the dose and schedule of the drugs to be administered....MORE
___________________________________________________________________________________________________
 Number: CALGB CTSU E1411 Principal Investigator: Bartlett, Nancy
Title: Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation; Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation; Arm C= Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation
Description: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and lenalidomide in treating previously untreated older patients with mantle cell lymphoma....MORE
___________________________________________________________________________________________________
 Number: CALGB 51101 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma
Description: The purpose of this research study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known....MORE
___________________________________________________________________________________________________
 Number: CALGB 50904 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lymphoma
Description: The purpose of this research study is to find out what effects (good and/or bad) treatment with the combination of ofatumumab and bendamustine or the combination of ofatumumab, bendamustine, and bortezomib has on patients and their lymphoma....MORE
___________________________________________________________________________________________________
 Number: AMC 075 Principal Investigator: Ratner, Lee
Title: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma
Description: This study is being conducted because scientists think that adding vorinostat therapy may enhance the effectiveness of standard chemotherapy plus rituximab in certain types of lymphoma, and may also have a positive effect against HIV and other viruses in our bodies which can cause lymphoma....MORE
___________________________________________________________________________________________________
 Number: 201505024 Principal Investigator: Bartlett, Nancy
Title: An Open-Label, Multicenter, Phase I trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Description: The purpose of this research study is to test the safety of BTCT4465A at different dose levels and to find out what effects, good or bad, BTCT4465A has on you and your cancer....MORE
___________________________________________________________________________________________________
 Number: 201411010 Principal Investigator: Fehniger, Todd
Title: A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
Description: The purpose of this research study is to test the safety of different doses of the study drug, ALT-803, when combined with the routine clinical (standard) therapy, rituximab. In this study we wish to find what the treatment side effects are and how well treatment with ALT-803 and rituximab is tolera...MORE
___________________________________________________________________________________________________
 Number: 201409114 Principal Investigator: Bartlett, Nancy
Title: Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Presence of the MyD88 L265P Mutation
Description: The purpose of this research study is to see if IMO-8400 is safe and effective in the treatment of patients with relapsed or refractory Diffuse Large B-Cell Lymphoma and MYD88 L265P mutation positive following conventional treatment. Examples of conventional treatment are radiotherapy, immunotherapy...MORE
___________________________________________________________________________________________________
 Number: 201408033 Principal Investigator: Bartlett, Nancy
Title: A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination with Localized Low-dose Radiation in Patients with Untreated Low-grade B-cell Lymphoma
Description: The purpose of this study is to learn about the safety of SD-101 and to find out what effects (both good and bad) it has on you and your B-cell Lymphoma when given along with low-dose radiation therapy. SD-101 is being studied as a treatment of Non-Hodgkin’s Lymphoma (NHL), specifically Low Grade B-...MORE
___________________________________________________________________________________________________
 Number: 201310010 Principal Investigator: Bartlett, Nancy
Title: A Phase Ib Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of DCDS4501A in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with B-Cell Non-Hodgkin's Lymphoma
Description: The purpose of this study is to test an investigational drug called DCDS4501A, in combination with four other drugs, rituximab (Rituxan®, MabThera®), cyclophosphamide, doxorubicin, and prednisone (when given together, referred to as R-CHP). We want to find out what effects, good and/or bad, these dr...MORE
___________________________________________________________________________________________________
 Number: 201305047 Principal Investigator: Bartlett, Nancy
Title: A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) as front-line therapy in patients with diffuse large B-cell lymphoma (DLBCL)
Description: This study is being done to test the safety and effectiveness of 2 different doses of brentuximab vedotin when given with a combination of drugs called RCHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (also called doxorubicin), vincristine (Oncovin), and prednisone]....MORE
___________________________________________________________________________________________________
 Number: 201301088 Principal Investigator: Bartlett, Nancy
Title: An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil) (PCYC-1116-CA)
Description: The purpose of this study is to provide patients who previously participatecd in the PCYC-115-CA study access to the investigational drug, PCI-32765 or alternative treatment....MORE
___________________________________________________________________________________________________
 Number: 201208155 Principal Investigator: Carson, Kenneth
Title: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Description: The purpose of this research study is to determine if KW-0761 will work against cutaneous T-cell lymphoma that has failed to respond to other treatments, and to evaluate its side effects....MORE
___________________________________________________________________________________________________
 Number: 201208075 Principal Investigator: Bartlett, Nancy
Title: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas SGN35-014)
Description: This is a clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas....MORE
___________________________________________________________________________________________________
 Number: 201109213 Principal Investigator: Bartlett, Nancy
Title: A Phase I Study of Pf-05082566 as a Single Agent in Patients with Advanced Cancer, And in Combination with Rituximab in Patients with Non-Hodgkin’s Lymphoma (NHL)
Description: The purpose of this research study is to learn about the effects of the study drug, PF-05082566, and to find the best dose for treating Non-Hodgkin’s lymphoma....MORE
___________________________________________________________________________________________________
 Number: 201108251 Principal Investigator: Cashen, Amanda
Title: Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of Lymphoid Malignancies
___________________________________________________________________________________________________
 Number: 201501102 Principal Investigator: Bartlett, Nancy
Title: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Description: The purpose of this research study is to determine if the investigational product, KTE-C19, when administered after you receive either a 3 or 7 day course of chemotherapy, is safe and effective in treating your disease. The sponsor is testing an investigational treatment named KTE-C19, which uses th...MORE
___________________________________________________________________________________________________
 Number: 201501033 Principal Investigator: Bartlett, Nancy
Title: A Phase 1, Open-Label,Multicenter Trial of Oral Azacitidine (CC486) Plus R-CHOP in Subjects with High Risk (IPI 3 Or More) Previously Untreated Diffuse Large BCell Lymphoma or Grade 3B Follicular Lymphoma (CC-486-DLBCL-001)
Description: The purpose of this study is to look at the safety of oral azacitidine when combined with R- CHOP (Rituximab “R”, cyclophosphamide “C”, doxorubicin “H”, vincristine “O”, and prednisone “P”, a combination of drugs normally used in treating Diffuse Large B-Cell Lymphoma or Grade 3B follicular lymphoma...MORE
___________________________________________________________________________________________________